AMRUTANJAN HEALTH CARE LTD.-$

Amrutanjan Health Care Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. This report, a mandatory part of the Annual Report under SEBI regulations, details the company's performance and initiatives related to environmental, social, and governance (ESG) factors. The company highlights its commitment to "Pure Healthy Essence," focusing on innovation, stakeholder interests, ethics, and individual/family well-being. Key areas of focus include expanding its product portfolio in pain management, women's hygiene, and personal care, with recent double-digit growth in pain management and women's hygiene segments. The company emphasizes its strategy of "Focused Execution, Stronger Momentum" through network strengthening and rural outreach.

Amrutanjan Health Care Ltd has announced its 89th Annual General Meeting (AGM) will be held on Wednesday, September 23, 2026, at 10:30 AM via Video Conferencing/Other Audio Visual Means (VC/OAVM). The notice of the AGM and the Annual Report for the Financial Year 2025-26 are available on the company's website. The report highlights the company's theme of 'Focused Execution, Stronger Momentum', emphasizing its journey from a single balm in 1893 to a diversified portfolio including pain management, women's hygiene, rehydration, and personal care. The company aims for a 33% CAGR growth, driven by innovation and a commitment to stakeholder interests, ethics, and natural, efficacious products.

Amrutanjan Health Care Ltd has announced that September 11, 2026, has been fixed as the record date for the payment of its final dividend for the financial year 2025-26. This date will determine the eligibility of shareholders for the dividend, based on their names appearing in the company's register of members and as beneficial owners as per details from NSDL and CDSL. The announcement also pertains to the Annual General Meeting (AGM).

Amrutanjan's standalone (its only reported basis — the company has no subsidiaries) PAT for Q1 FY27 came in at ₹4.37 Cr, down 47.5% year-on-year from ₹8.31 Cr and down 73.0% sequentially from ₹16.19 Cr in the seasonally strong Q4 FY26. Revenue rose 9.5% YoY to ₹102.97 Cr from ₹94.05 Cr but fell 31.3% QoQ from ₹149.77 Cr — the March quarter is the balm season peak, so the sequential drop is largely seasonal and not itself a red flag. Net margin compressed sharply to ~4.1% of total income, versus 8.44% a year ago and 10.48% last quarter. The headline decline is inflated by a one-off: a ₹2.03 Cr exceptional charge tied to settling a long-running Tamil Nadu HR&CE lease-rent dispute, under which the company paid ₹9.74 Cr in total arrears on August 1, 2026. Excluding this, pre-exceptional PBT was ₹8.10 Cr and adjusted PAT works out to roughly ₹5.82 Cr — still down about 29.9% YoY, so the underlying business, not just the one-off, is weaker. Segment data point to the source: the Women's Hygiene & Personal Care segment's loss widened to ₹2.88 Cr from a marginal ₹0.15 Cr profit a year ago, consistent with ramp-up costs from the newly commissioned ₹150 Cr sanitary napkin plant (announced August 5, 2026). Core OTC Products segment profit also slipped 8.5% YoY to ₹9.87 Cr from ₹10.79 Cr, while the Beverages segment's loss narrowed to ₹1.26 Cr from ₹3.00 Cr. No analyst consensus estimates for this quarter were found in a web search, and the company has no formal quarterly guidance on record in our data or online, so the print cannot be graded against a specific external bar; management's press release commentary was not available for this filing either. The lease-rent settlement and the plant commissioning both fell inside this quarter and, taken together, explain most of the swing in reported profitability. Separately, the board fixed September 11, 2026 as the record date for the final dividend and set the 89th AGM for September 23, 2026 — both administrative and unrelated to the operating numbers. Going forward, the print sets up two things to track: whether the Women's Hygiene segment's losses narrow as the new capacity ramps past its Q1 drag, and whether core OTC margins recover toward the ~12% pre-exceptional level seen a year ago now that the lease-rent matter appears settled.

Amrutanjan Health Care Ltd has filed a corporate announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. This filing pertains to additional details required for a previously submitted intimation dated August 5, 2026, concerning the credit rating received from Care Ratings Limited. The company is providing further information as requested by regulatory authorities.

Amrutanjan Health Care Ltd has announced that its Board of Directors will convene on August 11, 2026, in Hyderabad. The primary agenda item is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the statutory auditors' limited review report. The company also noted that the trading window for its equity shares remains closed from July 1, 2026, until August 13, 2026, in compliance with SEBI regulations.

Amrutanjan Health Care Ltd has commissioned its new Greenfield sanitary napkin manufacturing facility in Telangana, marking a significant milestone with a ₹150 crore investment. The state-of-the-art plant, spread across 10 acres, features automated production lines and a planned annual capacity of 700 million sanitary napkins under the Comfy brand. Strategically located near Hyderabad, the facility aims to leverage the region's industrial ecosystem and market access. It is expected to create 350 direct and indirect employment opportunities and incorporates sustainable practices like rainwater harvesting and waste recycling. This expansion aligns with the 'Make in India' initiative and strengthens Amrutanjan's position in the feminine hygiene market.

DSP Trustee Private Limited, on behalf of DSP Mutual Fund schemes, has sold 2,11,361 shares of Amrutanjan Health Care Ltd. This sale, executed on July 31, 2026, resulted in the fund's shareholding decreasing to 2.82% of the company's paid-up capital. This change exceeds the 2% threshold requiring disclosure under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. The disclosure was made on August 04, 2026.

Amrutanjan Health Care Ltd has paid lease rent arrears of ₹9,74,67,151/- to Kapaleeswarar Temple. This payment is in compliance with an order from the Hon'ble Madras High Court. The company's writ petition and appeal challenging a section of the Tamil Nadu Hindu Religious and Charitable Endowment Act, 1959, were dismissed. Despite the dismissal and the payment, the company states there is no significant impact on its business and operations.

Amrutanjan Health Care Ltd has announced the closure of its trading window for designated persons from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. Designated persons are prohibited from trading in the company's securities during this period to prevent insider trading.